Katsunori Shinozaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsunori Shinozaki has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Akihito Tsuji
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kita, Japan
20 shared publications - Toshifumi Yamaguchi
Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
20 shared publications - Hideaki Suna
Ono Pharmaceutical Co., Ltd., Osaka, Osaka, Japan
18 shared publications - Hiroki Hara
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
18 shared publications - Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
18 shared publications - Hiroshi Tanaka
Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan
18 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 120
Longitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study
Purpose Reliable circulating biomarkers for chemotherapy-induced peripheral neuropathy (CIPN) remain lacking. Phosphorylated neurofilament-heavy chain (pNF-H) is an axon-oriented biomarker of neuroaxonal injury, but its clinical relevance in oxaliplatin-induced peripheral neuropathy has not been established. We evaluated the feasibility and longitudinal behavior of plasma pNF-H in patients receiving oxaliplatin-based chemotherapy. Methods This prospective multi-institutional exploratory study included patients with unresectable or recurrent colorectal cancer receiving CapeOX plus bevacizumab as part of the NYX study, a randomised trial of ninjin’yoeito (NYT; TJ-108, Tsumura & Co., Tokyo, Japan), a twelve-ingredient Kampo herbal extract, at 9.0 g/day for 24 weeks in the NYT arm. Plasma samples were collected at baseline, at clinically assessed CIPN onset (follow-up 1), and at the time of neuropathy resolution, at cycle 9, or at discontinuation, whichever came first (follow-up 2). Plasma pNF-H concentrations were measured by enzyme-linked immunosorbent assay. CIPN was assessed using CTCAE version 5.0. Results Thirty patients with evaluable plasma samples were included. Plasma pNF-H levels showed substantial inter-individual variability without a consistent temporal pattern. Compared with baseline and CIPN onset, plasma pNF-H levels at follow-up 2 were modestly but significantly increased. However, plasma pNF-H levels were not associated with the onset, severity, or persistence of clinically assessed CIPN. Conclusions Although longitudinal plasma pNF-H measurement was technically feasible, pNF-H did not function as a clinically meaningful biomarker for oxaliplatin-induced peripheral neuropathy. These findings may reflect a pathophysiological mismatch between dorsal root ganglion neuronal cell body injury and the axon-oriented biological specificity of pNF-H.
- 14 October 2026
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 120
Open AccessLongitudinal plasma phosphorylated neurofilament-heavy chain levels in oxaliplatin-induced peripheral neuropathy: a prospective multi-institutional exploratory study
Purpose Reliable circulating biomarkers for chemotherapy-induced peripheral neuropathy (CIPN) remain lacking. Phosphorylated neurofilament-heavy chain (pNF-H) is an axon-oriented biomarker of neuroaxonal injury, but its clinical relevance in oxaliplatin-induced peripheral neuropathy has not been established. We evaluated the feasibility and longitudinal behavior of plasma pNF-H in patients receiving oxaliplatin-based chemotherapy. Methods This prospective multi-institutional exploratory study included patients with unresectable or recurrent colorectal cancer receiving CapeOX plus bevacizumab as part of the NYX study, a randomised trial of ninjin’yoeito (NYT; TJ-108, Tsumura & Co., Tokyo, Japan), a twelve-ingredient Kampo herbal extract, at 9.0 g/day for 24 weeks in the NYT arm. Plasma samples were collected at baseline, at clinically assessed CIPN onset (follow-up 1), and at the time of neuropathy resolution, at cycle 9, or at discontinuation, whichever came first (follow-up 2). Plasma pNF-H concentrations were measured by enzyme-linked immunosorbent assay. CIPN was assessed using CTCAE version 5.0. Results Thirty patients with evaluable plasma samples were included. Plasma pNF-H levels showed substantial inter-individual variability without a consistent temporal pattern. Compared with baseline and CIPN onset, plasma pNF-H levels at follow-up 2 were modestly but significantly increased. However, plasma pNF-H levels were not associated with the onset, severity, or persistence of clinically assessed CIPN. Conclusions Although longitudinal plasma pNF-H measurement was technically feasible, pNF-H did not function as a clinically meaningful biomarker for oxaliplatin-induced peripheral neuropathy. These findings may reflect a pathophysiological mismatch between dorsal root ganglion neuronal cell body injury and the axon-oriented biological specificity of pNF-H.
- Open Access
- 24 September 2026
- Published by Springer Nature in Research Square
Nutritional status and quality of life with or without Ninjin'yoeito during first-line chemotherapy for metastatic colorectal cancer: an exploratory, open-label randomized phase II trial
Purpose Cancer-associated malnutrition during chemotherapy may impair treatment tolerance and quality of life (QoL). Ninjin'yoeito (NYT), a Japanese Kampo medicine, is used to treat anorexia, fatigue, and general malaise. We evaluated NYT during first-line chemotherapy for metastatic colorectal cancer (mCRC). Methods This exploratory, open-label, multicenter, randomized phase II trial compared NYT plus CAPOX and bevacizumab with CAPOX and bevacizumab alone in patients with unresectable mCRC. Co-primary endpoints were longitudinal changes in Controlling Nutritional Status (CONUT) scores and grade ≥ 3 nonhematological adverse events. Secondary endpoints included body mass index (BMI), QoL, and progression-free survival (PFS). Results Enrollment was terminated early because of slow accrual. Of 78 randomized patients, 74 were included in the full analysis set (NYT, n = 39; non-NYT, n = 35). Neither co-primary endpoint differed significantly between groups: CONUT score changes (least-squares mean difference [LSMD], − 0.05; 95% confidence interval [CI], − 0.53 to 0.42; P = 0.822) and grade ≥ 3 nonhematological adverse events (25.6% vs 20.0%; P = 0.593). Exploratory analysis showed better BMI maintenance with NYT (LSMD, 0.66 kg/m²; 95% CI, 0.19–1.13; P = 0.007). Appetite loss was lower with NYT and remained significant in sensitivity analysis, whereas insomnia scores were higher. PFS did not differ significantly between groups (HR, 1.21; 95% CI, 0.44–3.33; log-rank P = 0.713). Conclusions NYT did not significantly affect either co-primary endpoint. Exploratory findings suggested better BMI maintenance and reduced appetite loss, whereas insomnia scores were higher. These findings are hypothesis-generating and require confirmation in adequately powered trials. Clinical trial registration This trial was registered in the Japan Registry of Clinical Trials (ID jRCTs041190071) on October 2, 2019.
- 24 September 2026
- Published by Springer Nature in Research Square
Open AccessNutritional status and quality of life with or without Ninjin'yoeito during first-line chemotherapy for metastatic colorectal cancer: an exploratory, open-label randomized phase II trial
Purpose Cancer-associated malnutrition during chemotherapy may impair treatment tolerance and quality of life (QoL). Ninjin'yoeito (NYT), a Japanese Kampo medicine, is used to treat anorexia, fatigue, and general malaise. We evaluated NYT during first-line chemotherapy for metastatic colorectal cancer (mCRC). Methods This exploratory, open-label, multicenter, randomized phase II trial compared NYT plus CAPOX and bevacizumab with CAPOX and bevacizumab alone in patients with unresectable mCRC. Co-primary endpoints were longitudinal changes in Controlling Nutritional Status (CONUT) scores and grade ≥ 3 nonhematological adverse events. Secondary endpoints included body mass index (BMI), QoL, and progression-free survival (PFS). Results Enrollment was terminated early because of slow accrual. Of 78 randomized patients, 74 were included in the full analysis set (NYT, n = 39; non-NYT, n = 35). Neither co-primary endpoint differed significantly between groups: CONUT score changes (least-squares mean difference [LSMD], − 0.05; 95% confidence interval [CI], − 0.53 to 0.42; P = 0.822) and grade ≥ 3 nonhematological adverse events (25.6% vs 20.0%; P = 0.593). Exploratory analysis showed better BMI maintenance with NYT (LSMD, 0.66 kg/m²; 95% CI, 0.19–1.13; P = 0.007). Appetite loss was lower with NYT and remained significant in sensitivity analysis, whereas insomnia scores were higher. PFS did not differ significantly between groups (HR, 1.21; 95% CI, 0.44–3.33; log-rank P = 0.713). Conclusions NYT did not significantly affect either co-primary endpoint. Exploratory findings suggested better BMI maintenance and reduced appetite loss, whereas insomnia scores were higher. These findings are hypothesis-generating and require confirmation in adequately powered trials. Clinical trial registration This trial was registered in the Japan Registry of Clinical Trials (ID jRCTs041190071) on October 2, 2019.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Representativeness of study participants
- Open Access
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- 14 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
The antibodies list used for TIL analysis
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Evaluation of PD-1+ Treg cells and PD-1+CD8+ T cells. A and B, The scatter plots that show PD-1 positivity (%) in CD8+ T cells and Treg cells in patients with (A) NSCLC and (B) gastric cancer (GC). Straight line indicates PD-1 positivity (%) in CD8+ T cells/PD-1 positivity (%) in Treg cells of ≥1.
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Evaluation of PD-1+ Treg cells and PD-1+CD8+ T cells. A and B, The scatter plots that show PD-1 positivity (%) in CD8+ T cells and Treg cells in patients with (A) NSCLC and (B) gastric cancer (GC). Straight line indicates PD-1 positivity (%) in CD8+ T cells/PD-1 positivity (%) in Treg cells of ≥1.
- Open Access
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
- 13 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study